Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Key facts

Sponsor

ECOG-ACRIN Cancer Research Group

Principal Investigator

Pamela Kunz, M.D

ECOG-ACRIN Cancer Research Group

Intervention

temozolomide(drug)

Enrollment

144 enrolled

Eligibility

18 years · All sexes

Timeline

2013 – 2026

Study locations (30)

• Kaiser Anaheim Medical Center, Anaheim, California, United States
• Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
• Kaiser Permanente Medical Group - Baldwin Park, Baldwin Park, California, United States
• Kaiser Foundation Hospital, Bellflower, California, United States
• Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
• Mills - Peninsula Hospitals, Burlingame, California, United States
• Kaiser Permanente Hospital, Fontana, California, United States
• Kaiser Permanente, Fremont, Fremont, California, United States
• Kaiser Permanente, Fresno, California, United States
• Kaiser Permanente - Harbor City, Harbor City, California, United States
• Kaiser Permanente, Hayward, Hayward, California, United States
• Southern California Permanente Medical Group, Irvine, California, United States
• Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
• University of Southern California/Norris Cancer Center, Los Angeles, California, United States
• Kaiser Permanente-West Los Angeles, Los Angeles, California, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.